Drug Profile
YLS 1501
Alternative Names: YLS1501Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Yungjin Pharm Co
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Spinal stenosis
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for phase-I development in Spinal-stenosis in South Korea (PO, Controlled release)
- 20 Jan 2016 Phase-I clinical trials in Spinal stenosis in South Korea (unspecified route) prior to January 2016 (Yungjin Pharm's pipeline, January 2016)